WO2026005647A3 - Agent immunobiologique pour traiter des maladies oncologiques sur la base d'un vecteur arn - Google Patents

Agent immunobiologique pour traiter des maladies oncologiques sur la base d'un vecteur arn

Info

Publication number
WO2026005647A3
WO2026005647A3 PCT/RU2025/000257 RU2025000257W WO2026005647A3 WO 2026005647 A3 WO2026005647 A3 WO 2026005647A3 RU 2025000257 W RU2025000257 W RU 2025000257W WO 2026005647 A3 WO2026005647 A3 WO 2026005647A3
Authority
WO
WIPO (PCT)
Prior art keywords
seq
cancerous diseases
agent
proposed
mrna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/RU2025/000257
Other languages
English (en)
Russian (ru)
Other versions
WO2026005647A2 (fr
Inventor
Александр Леонидович ГИНЦБУРГ
Андрей Дмитриевич КАПРИН
Денис Юрьевич ЛОГУНОВ
Владимир Алексеевич ГУЩИН
Амир Ильдарович ТУХВАТУЛИН
Наталья Михайловна Тухватулина
Софья Рубеновна КОЗЛОВА
Наталия Петровна АНТОНОВА
Елена Владимировна ШИДЛОВСКАЯ
Бахтияр Исраил оглы ВЕРДИЕВ
Роман Алексеевич ИВАНОВ
Денис Александрович КЛЕЙМЕНОВ
Евгения Николаевна БЫКОНЯ
Елена Петровна МАЗУНИНА
Алина Шахмировна ДЖАРУЛЛАЕВА
Андрей Андреевич ПОЧТОВЫЙ
Андрей Эдуардович СИНЯВИН
Евгений Валерьевич УСАЧЕВ
Дарья Владимировна ВАСИНА
Надежда Анатольевна КУЗНЕЦОВА
Сергей Евгеньевич ДМИТРИЕВ
Игорь Андреевич ИВАНОВ
Ирина Леонидовна ТУТЫХИНА
Тимофей Андреевич РЕМИЗОВ
Анастасия Андреевна ЗАХАРОВА
Александр Сергеевич Семихин
Андрей Игоревич ГОСУДАРЕВ
Дмитрий Николаевич ЩЕРБИНИН
Елизавета Александровна ТОКАРСКАЯ
Надежда Леонидовна ЛУБЕНЕЦ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Federal State Budgetary Institution "national Research Center Of Epidemiology And Microbiology Named After Honorary Academician NF Gamalei" Of Ministry Of Health Of Russian Federation
Original Assignee
Federal State Budgetary Institution "national Research Center Of Epidemiology And Microbiology Named After Honorary Academician NF Gamalei" Of Ministry Of Health Of Russian Federation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2024118081A external-priority patent/RU2828631C1/ru
Application filed by Federal State Budgetary Institution "national Research Center Of Epidemiology And Microbiology Named After Honorary Academician NF Gamalei" Of Ministry Of Health Of Russian Federation filed Critical Federal State Budgetary Institution "national Research Center Of Epidemiology And Microbiology Named After Honorary Academician NF Gamalei" Of Ministry Of Health Of Russian Federation
Publication of WO2026005647A2 publication Critical patent/WO2026005647A2/fr
Publication of WO2026005647A3 publication Critical patent/WO2026005647A3/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Ce groupe d'inventions se rapporte au domaine de l'immunologie et de l'oncologie. Cet agent immunobiologique peut être utilisé dans le traitement de patients soufrant de maladies oncologiques d'étiologies différentes. L'invention concerne un agent à base d'un vecteur ARNm, dans lequel l'ARNm comprend une séquence SEQ ID NO:l, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:8 à la 5' extrémité; un cadre de réticulation ouvert codant de 1 à 80 signatures gènes tumoraux; et une séquence SEQ ID NO:6 ou SEQ ID NO:7 à la 3' extrémité. L'invention concerne également un procédé de production de l'agent et son utilisation. Ce groupe d'inventions permet d'élargir l'éventail des moyens et des procédés pour induire une réponse immune chez des patients soufrant de maladies oncologiques.
PCT/RU2025/000257 2024-06-29 2025-08-28 Agent immunobiologique pour traiter des maladies oncologiques sur la base d'un vecteur arn Pending WO2026005647A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2024118081 2024-06-29
RU2024118081A RU2828631C1 (ru) 2024-06-29 Иммунобиологическое средство для терапии онкологических заболеваний на основе мРНК вектора.

Publications (2)

Publication Number Publication Date
WO2026005647A2 WO2026005647A2 (fr) 2026-01-02
WO2026005647A3 true WO2026005647A3 (fr) 2026-02-19

Family

ID=98222644

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2025/000257 Pending WO2026005647A2 (fr) 2024-06-29 2025-08-28 Agent immunobiologique pour traiter des maladies oncologiques sur la base d'un vecteur arn

Country Status (1)

Country Link
WO (1) WO2026005647A2 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2550267C2 (ru) * 2012-12-12 2015-05-10 Елена Андреевна Чирясова Способ воздействия на пролиферативный статус клеток с помощью специфических нуклеотидных последовательностей g-цепи теломерной днк человека
WO2018144082A1 (fr) * 2017-02-01 2018-08-09 Modernatx, Inc. Vaccins anticancéreux à arn
JP2019054813A (ja) * 2012-04-02 2019-04-11 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． ヒト疾患に関連するタンパク質の産生のための修飾ポリヌクレオチド
US11162102B2 (en) * 2019-05-13 2021-11-02 Dna Twopointo Inc. Modifications of mammalian cells using artificial micro-RNA to alter their properties and the compositions of their products
RU2765729C1 (ru) * 2021-12-29 2022-02-02 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Иммунобиологическое средство для индукции иммунного ответа против SARS-CoV-2 и способ его применения (варианты)
US11827922B2 (en) * 2018-03-07 2023-11-28 Wisconsin Alumni Research Foundation High throughput nucleic acid profiling of single cells

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019054813A (ja) * 2012-04-02 2019-04-11 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． ヒト疾患に関連するタンパク質の産生のための修飾ポリヌクレオチド
RU2550267C2 (ru) * 2012-12-12 2015-05-10 Елена Андреевна Чирясова Способ воздействия на пролиферативный статус клеток с помощью специфических нуклеотидных последовательностей g-цепи теломерной днк человека
WO2018144082A1 (fr) * 2017-02-01 2018-08-09 Modernatx, Inc. Vaccins anticancéreux à arn
US11827922B2 (en) * 2018-03-07 2023-11-28 Wisconsin Alumni Research Foundation High throughput nucleic acid profiling of single cells
US11162102B2 (en) * 2019-05-13 2021-11-02 Dna Twopointo Inc. Modifications of mammalian cells using artificial micro-RNA to alter their properties and the compositions of their products
RU2765729C1 (ru) * 2021-12-29 2022-02-02 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Иммунобиологическое средство для индукции иммунного ответа против SARS-CoV-2 и способ его применения (варианты)

Also Published As

Publication number Publication date
WO2026005647A2 (fr) 2026-01-02

Similar Documents

Publication Publication Date Title
AU1254795A (en) Tumor necrosis factor-gamma
WO2022150732A3 (fr) Thérapie par récepteur chimérique
ZA200509606B (en) Prostate stem cell antigen (PSCA) variants and subsequences thereof
DE69617440D1 (de) Isolierte nukleinsäuremoleküle, peptide die mit hla-a2 moleküle (mhc) komplexe bilden, sowie deren verwendungen
CN103333913A (zh) 可以分泌表达超氧化物歧化酶的工程酿酒酵母及其构建方法与其在制备活性美容产品中的应用
CA2208524A1 (fr) Administration de molecules d'acide nucleique a des tissus muqueux
Liu et al. Preparation of a nanobody specific to dectin 1 and its anti-inflammatory effects on fungal keratitis
DE60038680D1 (de) Antisense-therapie für hormonregulierte tumoren
MX2023012766A (es) Metodo para permitir la infiltracion de las celulas inmunitarias en los tumores.
Qian et al. The application of antibody-based agents in cancer therapy based on their mechanisms of action
WO2003085087A3 (fr) Acide nucleique d'antigene carcinoembryonnaire modifie et vecteurs d'expression
WO2021011844A3 (fr) Agents et méthodes de polythérapie contre le cancer
CN113583124B (zh) 一种抗前胃泌素释放肽单克隆抗体及其制备方法
CN101648011B (zh) 一种肿瘤靶向重组dna疫苗及其制备与应用
CN120000686A (zh) 一种高熵合金纳米颗粒及其应用
CN105254744A (zh) 多肽xzz-5的异源表达及其在增强cik细胞杀瘤活性中的应用
WO2002043651A8 (fr) Methodes d'utilisation de lymphocytes t mis en culture et n'induisant pas de reaction du greffon contre l'hote (gvhd) pour traiter des maladies
JP2003521439A5 (fr)
CN105483086B (zh) 一种脑胶质瘤细胞及其用途
BE896895A (fr) Enzyme analogue a la pepsine leucocytaire humaine et compositions et agents therapeutiques qui la contiennent.
CN102719441A (zh) 旋毛虫与乳腺癌相关抗原基因ts498抗体制备方法
Dutta et al. Expression of DNA sequences containing neuron specific enolase gene in Scherichia Coli
WO2024040030A3 (fr) Traitement de troubles de mauvais repliement des protéines
Toll The EADO staging system for Basal Cell Carcinoma predicts the utility of vismodegib in neoadjuvancy before surgery
WO2024259186A3 (fr) Thérapie car-t cd74 et ses procédés d'utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 25827411

Country of ref document: EP

Kind code of ref document: A2